Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer

ConclusionWhen dosed according to BSA calculated using actual body weight there is no significant difference in paclitaxel exposure between normal and overweight women. Using alternative descriptors of weight to calculate BSA could lead to under ‐dosing of this drug.Trial registrationThis study is registered in the Clinical Trials Registry of India CTRI/2015/09/006193.

Source: Cancer Medicine - April 7, 2021 Category: Cancer & Oncology Authors: Vikram Gota, Manjunath Nookala, Avinash Bonda, Ashwin Karanam, Bharati Shriyan, Yogesh Kembhavi, Murari Gurjar, Anand Patil, Ashish Singh, Navin Goyal, Sudeep Gupta Tags: ORIGINAL RESEARCH Source Type: research